Synthesis 2009(21): 3589-3592  
DOI: 10.1055/s-0029-1216978
PAPER
© Georg Thieme Verlag Stuttgart ˙ New York

Prompt Lithiation of 1-Dimethylsulfamoylthymine Used for the Synthesis of 1-Allyloxymethyl-6-(α,2,6-trifluorobenzyl)thymine

Yasser M. Lokshaa, Erik B. Pedersen*a, Andrew D. Bondb, Paolo La Collac, Barbara Seccic, Roberta Loddoc
a Nucleic Acid Centre, Department of Physics and Chemistry, University of Southern Denmark, Campusvej 55, 5230 Odense M, Denmark
Fax: +4566158780; e-Mail: ebp@ifk.sdu.dk;
b Department of Physics and Chemistry, University of Southern Denmark, Campusvej 55, 5230 Odense M, Denmark
c Dipartimento di Scienze e Tecnologie Biomediche, Sezione di Microbiologia e Virologia Generale e Biotecnologie Microbiche, Università di Cagliari, Cittadella Universitaria, 09042 Monserrato, Italy
Further Information

Publication History

Received 16 March 2009
Publication Date:
28 August 2009 (online)

Abstract

The 6-position of the uracil ring was activated for a lithiation reaction by condensing thymine with dimethylsulfamoyl chloride. X-ray crystallography was used to confirm the structure of the intermediate product 1-dimethylsulfamoylthymine, which was lithiated and subsequently treated with 2,6-difluorobenzaldehyde. The dimethylsulfamoyl group was removed by treatment with aq HCl and the alcohol was fluorinated with DAST. The fluoro-derivative was silylated and alkylated at the N1-position with bis(allyl­oxy)methane to give 1-allyloxymethyl-6-[(2,6-difluoro­phen­yl)fluo-romethyl]-5-methylpyrimidine-2,4(1H,3H)-dione, which showed moderate activity against HIV-1. An attempt was also made to activate 5-methyl-2-(methylthio)pyrimidin-4(3H)-one with dimethylsulfamoyl chloride for a lithiation reaction. However, X-ray crystallography and subsequent reactions showed that the sulfamoylation had taken place on the oxygen at the 4-position.

    References

  • 1 Baba M. Shigeta S. Yuasa S. Takashima H. Sekiya K. Ubasawa M. Tanaka H. Miyasaka T. Walker RT. De Clercq E. Antimicrob. Agents Chemother.  1994,  38:  688 
  • 2 Yuasa S. Sadakata Y. Takashima H. Sekiya K. Inouye N. Ubasawa M. Baba M. Mol. Pharmacol.  1993,  44:  895 
  • 3 Mai A. Artico M. Sbardella G. Massa S. Loi AG. Tramontano E. Scano P. La Colla P. J. Med. Chem.  1995,  38:  2860 
  • 4 Baba M. Tanaka H. De Clercq E. Pauwels R. Balzarini J. Schols D. Nakashima H. Perno C.-F. Walker RT. Miyasaka T. Biochem. Biophys. Res. Commun.  1989,  165:  1375 
  • 5 Miyasaka T. Tanaka H. Baba M. Hayakawa H. Walker RT. Balzarini J. De Clercq E. J. Med. Chem.  1989,  32:  2507 
  • 6 Petersen L. Jessen CH. Pedersen EB. Nielsen C. Org. Biomol. Chem.  2003,  1:  3541 
  • 7 Meng G. Kuang Y.-Y. Ji L. Chen F.-E. Synth. Commun.  2005,  35:  1095 
  • 8 Kumarasinghe ES. Peterson MA. Robins MJ. Tetrahedron Lett.  2000,  41:  8741 
  • 9 Boudet N. Knochel P. Org. Lett.  2006,  8:  3737 
  • 10 Kopp F. Knochel P. Org. Lett.  2007,  9:  1639 
  • 11 El-Brollosy NR. Sørensen ER. Pedersen EB. Sanna G. La Colla P. Loddo R. Arch. Pharm.  2008,  341:  9 
  • 12 Loksha YM. El-Barbary AA. El-Badawi MA. Nielsen C. Pedersen EB. Synthesis  2004,  116 
  • 13 Turner RM. Lindell SD. Ley SV. J. Org. Chem.  1991,  56:  5739 
  • 14 Winter J. Retey J. Synthesis  1994,  245 
  • 15 Sahli S. Stump B. Welti T. Schweizer WB. Diederich F. Blum-Kaelin D. Aebi JD. Boehm H.-J. Helv. Chim. Acta  2005,  88:  707 
  • 16 Madsen C. Jensen AA. Liljefors T. Kristiansen U. Nielsen B. Hansen CP. Larsen M. Ebert B. Bang-Andersen B. Krogsgaard-Larsen P. Froelund B. J. Med. Chem.  2007,  50:  4147 
  • 17 Guianvarc’h D. Fourrey J.-L. Maurisse R. Sun J.-S. Benhida R. Org. Lett.  2002,  4:  4209 
  • 18 El-Brollosy NR. Jørgensen PT. Dahan B. Boel AM. Pedersen EB. Nielsen C. J. Med. Chem.  2002,  45:  5721 
19

The information in this document is provided as is and no guarantee or warranty is given that the information is fit for any particular purpose. The user thereof uses the information as its sole risk and liability.